SCHEMBL17315091

SCHEMBL17315091

c1ccc(CN2CCC(CCc3noc4c5c(ccc34)NCC5)CC2)cc1

nearest known ligand 0.71

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 20/20 0.71
▸ BCHE P06276 4/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL222186 0.83 ACHE (1.00) ACHEBCHE
SCHEMBL27336982 0.81 ACHE (0.68) ACHEBCHE
SCHEMBL6985471 0.76 ACHE (1.00) ACHEBCHE
SCHEMBL4488641 0.76 ACHE (0.79) ACHEBCHE
SCHEMBL9411285 0.76 ACHE (0.75) ACHEBCHE
SCHEMBL6985773 0.75 ACHE (1.00) ACHEBCHE
SCHEMBL4418006 0.75 ACHE (0.60) ACHEBCHE
Dimethylamine SCHEMBL4120318 0.75 ACHE (0.63) ACHEBCHE
SCHEMBL4125158 0.75 ACHE (0.62) ACHEBCHE
SCHEMBL13597349 0.74 ACHE (0.62) ACHEBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3149016-A1 PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2017-04-05 — — EP disclosed
WO-2015186068-A1 PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2015-12-10 — — WO disclosed
Send feedback